Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Diseasemodifying therapies are now being classified into categories based on level of efficacy. Strategies to use diseasemodifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis.
Introduction
Multiple sclerosis (MS) is characterized by immunemediated, demyelinating attacks on the central nervous system (CNS) resulting in fully or partially reversible neurologic syndromes or relapses. An MS relapse typically comes on acutely or subacutely, lasts days to weeks, and gradually remits. Radiographic evidence of inflammatory attacks can be seen anywhere in the white and grey matter of the CNS. Symptoms reflect lesion locations although silent lesions occur as well. Acute optic neuritis is the most common neurologic syndrome at onset. [1] [2] [3] [4] Other symptoms may occur throughout the disease such as cognitive impairment, fatigue, bowel and bladder disturbances, and spasticity. [2] [3] [4] Epidemiology, Phenotypes (Clinical Course), and Diagnosis Nearly one million persons are currently living with MS in the United States. 5 Multiple sclerosis is most commonly diagnosed in females and at age 20 to 50 years. 6 More than 80% of persons with MS (pwMS) have relapsing remitting MS (RRMS). Approximately 15% to 30% of pwMS will gradually evolve from RR to secondary progressive (SP) 15 to 20 years after onset. Previous natural history studies reported that 25% to 40% of pwMS develop SPMS, likely reflecting the lack of earlier diagnosis and use of DMTs. Roughly 15% of pwMS have a primary progressive (PP) course from the onset. [7] [8] [9] [10] A relapsing or progressive phenotype has been used since 1996 to describe a person's MS. In 2013, these phenotypes were modernized to better inform prognostication and treatment decision making by addressing limitations of the older phenotypes (Table 1) . 9, 10 The core clinical phenotypes of RR, SP, PP were retained, clinically isolated syndrome was officially added, but the confusing progressive relapsing phenotype was removed. Radiologically isolated syndrome or the incidental findings of MS-like lesions on brain magnetic resonance imaging (MRI), was not added since MRI findings without clinical evidence of demyelination may be nonspecific. Descriptive modifiers were introduced to provide more clinically useful information when communicating phenotype including active and not active to describe disease activity (recent relapse or CNS imaging activity) and with progression and without progression to describe disease worsening. As of May of 2019, the Food and Drug Administration (FDA) approved labeling of every DMT has been updated with these modifiers.
The McDonald's diagnostic criteria routinely undergoes revisions aligning the criteria with advancements in clinical and imaging technologies. Diagnosis is based on parameters such as medical history and neurological exam, as well as paraclinical parameters such as MRI, cerebrospinal fluid showing oligoclonal banding (sign of CNS inflammation), and evoked potentials (a measure of electrical activity in the brain). MRI remains the most sensitive tool available for determining events that meet diagnostic criteria for dissemination in time and space. The 2017 McDonald's diagnostic criteria 11 revision allows for earlier diagnosis of MS in individuals with typical clinically isolated syndrome if either imaging shows both symptomatic and asymptomatic MRI lesions or if cerebrospinal fluid is positive for oligoclonal banding. MRI scans may be used to obtain objective evidence to track treatment efficacy and adverse effects ( Table 2 ). 12
Patient Case Part 1: Risk Factors
A 27-year-old presents to the clinic with new onset numbness and tingling of the left buttock, leg, and foot along with lightheadedness and fecal incontinence. Brain MRI showed 2 new T2-lesions and cervical spine MRI showed 1 new T2-lesion, resulting in a diagnosis of RRMS. The patient exercises 4 times weekly, smokes 1 pack per day, has 2 to 3 alcoholic beverages per month, and expresses interested in natural remedies and lifestyle changes when discussing treatment options.
The incidence of MS in the United States is greater at higher latitudes. 5 This prevalence gradient may be related to less ultraviolet B-induced vitamin D production in the skin due to less sun exposure. Vitamin D appears to have protective anti-inflammatory and immunoregulatory effects. 2 Other immunologic, infectious, genetic, and environmental etiological factors have also been identified. [1] [2] [3] [4] Patients should be educated on the etiological factors that are modifiable if applicable, where interven- tion may either lower the risk of developing MS or if diagnosed, may weaken its influence on the rate of disease progression (Table 3) . 13, 14 Predicting the course of a pwMS is difficult since the disease manifests heterogeneously from one individual to another. Several factors can discern which pwMS may be at greater risk for a more aggressive course. 15, 16 The strongest and most consistent negative prognostic factors include: frequent relapses during the first 2 to 5 years postonset, short interval between relapses, incomplete relapse recovery, sphincter-type symptoms (ie, bowel, bladder), progression at onset, and rapidly worsening disability. 15, 16 Imaging characteristics include increasing size of T2 lesion burden from baseline, GAD lesions, cerebellar and/or spinal cord lesions, and brain atrophy. 16 Identifying the presence of negative prognostic factors and, thereby, patients at greater risk of disease worsening, informs clinicians which patients may benefit from earlier initiation of higher efficacy DMT.
Patient Case Part 2: Too Many Choices
Based on formulary options, copay assistance programs, and patient preference for route of administration, interferon-betas, fingolimod, and teriflunomide are DMT options discussed with the patient during a shareddecision making conversation.
Personalizing Treatment
The newer DMTs affect immune system functioning more directly compared to older self-injectable DMTs by targeting T-cell activation, T-cell migration, T-and/or Bcell depletion. When selecting a DMT, consider patientspecific factors and treatment approach. In the case example, affordability as well as oral and injectable options were discussed given the patient did not want to consider an infused therapy option. Although selfinjectable interferon-betas were the mainstay of MS management for many years, the self-injectable adminis-tration may not be ideal, primarily because of the risk of flu-like symptoms and injection-site reactions. Teriflunomide and fingolimod provide oral options but differ in their efficacy, safety, and side effect profiles ( Table 4 ). [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] While teriflunomide does have a risk of some worrisome side effects, (eg, hepatotoxicity, leukopenia, paresthesia), overall it has demonstrated similar or better tolerability compared to other oral DMTs in observational studies. 30, 31 The most important clinical risks with teriflunomide include hepatotoxicity (managed with routine laboratory monitoring), and teratogenicity. Another important factor for DMT decision-making is desire/plan for pregnancy. While specific management strategies for managing MS in preparation of and during pregnancy are out of the scope of this review, contraception and family planning should be discussed with every patient. Although safety of DMT use in pregnancy varies among agents, experts recommend highly effective contraception should be considered in all patients starting DMTs. 32 Individuals with decreased cutaneous production or consumption of vitamin D * Increased risk of relapses * Empiric vitamin D3 is 800 IU to 4000 IU daily is recommended Tobacco smoking * Progress to secondary progressive MS at a faster rate than non-smokers with greater risk of increasing disability * May not achieve optimal benefit of MS disease-modifying therapies * Quitting smoking delays experiencing disability progression and lessens the influence on relapses. Obesity * Occurring especially during childhood and adolescence (and in females) increases the risk for developing MS and for disease activity in persons with MS MS ¼ multiple sclerosis. Starter pack with slow dose titration reduces need for FDO requirement Despite increased receptor selectivity, risk of adverse effects appears similar to fingolimod Suspect rebound will be a concern here too (given mechanism of action) and risk of skin cancers The vast majority of PML cases occur in patients previously exposed to natalizumab. For some, the switch from natalizumab was prompted by an anti-JCV antibody positive status and/or more than 2 years of treatment. In cases of no prior natalizumab exposure, some PML cases were associated rarely with severe lymphopenia (as with dimethyl fumarate) or with prior history/concomitant use of immunosuppressing therapies. For these reasons, risk of PML for nonnatalizumab DMTs is overall considered to be low. 
Determining Modestly Effective Versus Highly Effective DMTs
The variable efficacy and side effect profiles of currently approved DMTs (Table 4 ) have introduced the idea of personalizing MS care.
Based on the available evidence, there is a generally accepted categorization of modestly effective (ME)-DMTs versus highly effective (HE)-DMTs (Table 4) , however controversy and differences in clinical opinion still exists. 15, 33 The increased efficacy of many of the newer DMTs exposes pwMS to DMTs with higher risks (eg, adverse effect potential, more complex safety monitoring needed). This increased risk potential is related to the newer agents having more immunosuppressing mechanisms (suppressing the immune response) versus the immunomodulating mechanisms (adjusting level of immune response) of the first available DMTs.
Determining ME-DMT versus HE-DMT for relapsing type of MS is not entirely straightforward given an overall lack of head-to-head trials between newer and older DMTs.
Previous head-to-head trials [34] [35] [36] [37] [38] between older selfinjectable agents have shown similar efficacy across agents. While one trial 38 showed superiority of one interferon-beta over another (eg, high-dose interferon vs low-dose interferon) this trial had design limitations lessening the strength of the result. The available phase III head-to-head trials and comparative effectiveness research between interferon-betas and the oral DMTs suggest teriflunomide is as effective as the interferonbetas and fingolimod is more effective than interferonbetas. 39, 40 The placebo-controlled studies [24] [25] [26] [27] of dimethyl fumarate included glatiramer acetate as a reference comparator, and thus were not designed to test the superiority or noninferiority of dimethyl fumarate versus glatiramer acetate. Prospective head-to-head studies among the HE-DMTs remain absent. Fortunately, observational and comparative effectiveness studies 30, 31, 39, 44, 45 showing HE-DMTs are more effective than ME-DMTs and describing long-term safety are providing real world data and supplementing the evidence given the limited number of head-to-head phase III trials.
With limited head-to-head data, clinicians are also left with comparing DMT efficacy outcomes such as annualized relapse reduction, incidence of new brain lesions on MRI, and disability scores, across placebo-controlled clinical trials. This practice comes with its own set of confounding factors and limitations making it difficult to compare these agents. For example, clinical trials vary by patient population and inclusion/exclusion criteria. Additionally, the diagnostic criteria for MS and definition of clinical relapse have changed and evolved over the years, making it difficult to compare recent studies to older clinical trials.
Patient Case Part 3: To Induce or Not to Induce
At the next clinic visit, the clinician and the patient discussed the goals and expectations of therapy and compared the efficacy and safety of the DMT options.
Given the approval of more efficacious DMTs, a broad evolution of the current MS treatment paradigm is underway. The key evolving concepts include treatment initiation and goals, stratifying treatment on disease phenotype and DMT efficacy, and managing use of riskier DMTs.
Goals of Treatment and Treatment Strategy
Prior to the availability of HE-DMTs, treatment response was demonstrated by achieving limited reduction in relapse rates and minimal effects on disability accumulation. Following the approval of HE-DMTs, the goals of treatment response have started to shift from reluctant acceptance of a partial response to the expectation of achieving as close to complete cessation of disease activity and progression as possible. 46 The no evidence of disease activity (NEDA) treatment goal remains controversial because of a lack of definition for how to measure disability progression clinically, MRI sensitivity for detecting lesions associated with disability, and real-world application. 46 The most agreed upon definition includes the absence of relapses, no confirmed disability progression, and no new GAD lesions or new or worsened T2 lesions. 46, 47 Using NEDA as a treatment goal means any evidence of relapse, progression, and/or active lesions should prompt reconsideration of the current DMT. Two therapeutic strategies are being examined to determine which best achieves a NEDA-like target.
The escalation strategy means starting with safer ME-DMTs and then transitioning to higher risk HE-DMTs only if disease breakthrough occurs. The argument against this strategy is that the early use of subpotent DMTs may expose individuals unnecessarily to the loss of functional years from disability accumulation because relapses are frequently underreported and silent lesions often occur. 48, 49 The induction strategy means that the higher risk, HE-DMTs are started immediately following diagnosis, in order to achieve the NEDA-like target as early as possible. Alemtuzumab and cladribine are considered inductionspecific DMTs given their relatively rapid suppression of multiple cell lines and persistent immunosuppression. Repopulation of these cell lines may take months to years thus, fostering long term suppression of disease activity. Induction therapy is then followed by long-term maintenance treatment, such as with a ME-DMT. 50 Rituximab and ocrelizumab are also HE-DMTs, though these agents have partial induction effects. While they do not suppress multiple immune cell lines, their duration of effect is prolonged and repeat dosing can be given at extended intervals (ie, every 9 to 12 months or longer if needed) over time. Natalizumab and fingolimod are HE-DMTs and are used as initial treatments for aggressive disease in a manner similar to induction-specific DMTs, but they do not have true induction effects. Both natalizumab and fingolimod (and likely siponimod) appear to have rapidly reversible effects that predispose patients to a rebound of disease activity upon discontinuation. 50 The overall concern with the induction approach is that an otherwise young, healthy person may be exposed to serious adverse effects including risk of opportunistic infections.
The recently updated treatment guidelines published by the American Academy of Neurology (AAN) 51 Additionally, inform the patient that even though the disease may appear dormant, silent inflammatory attacks and progression may be ongoing. 15, 16 For pwMS with any negative prognostic factor, we suggest HE-DMT from the start (induction strategy) along with education of the risks and careful monitoring of side effects.
Patient Case Part 4: De-Risking the Risk
The clinician supports the choice of fingolimod as an induction therapy given findings of spinal cord lesions and sphincter symptoms (fecal incontinence). Appropriate screening is completed and fingolimod is initiated with the recommended first dose observation (FDO) including a baseline electrocardiogram, blood pressure, and heart rate followed by blood pressure and heart rate checks hourly for 6 hours after the first dose is taken, and finally a repeat electrocardiogram at the 6 hour mark. The FDO of fingolimod is tolerated and treatment is started, after which the clinical pharmacy specialist assists with implementation of safety monitoring.
The clinical pharmacy specialist recommends absolute lymphocyte count (ALC) and liver function test (LFT) monitoring every 6 months while on fingolimod. At 6 months postinitiation, LFTs remain normal however, ALC falls to 300/lL. The patient denies any signs or symptoms of infection. The primary care provider orders a repeat complete blood count in 2 weeks and shows stable ALC, which remained at 300/lL.
Absolute lymphocyte count reduction is expected with fingolimod based on the mechanism of action of sequestering lymphocytes in lymphoid tissue and should not prompt therapy discontinuation. The lowest acceptable level of lymphopenia has been set to 200/lL because during clinical trials opportunistic infections were not seen even when the ALC dropped to this value. However risk of infection is unknown when ALCs are below this threshold as continuing fingolimod in this setting has not been extensively studied. 54 If ALC values fall persistently below 200/lL, an alternative DMT should be considered. Holding fingolimod therapy to allow ALC to increase within an acceptable range may be tried. However, if treatment is interrupted for more than 14 days, FDO for cardiac changes is recommended upon reinitiation.
Siponimod and dimethyl fumarate can also reduce ALC. 21, 26 Because of a similar mechanism of action to fingolimod, ALC reduction with siponimod is expected and thus management recommendations are similar. Lymphopenia with dimethyl fumarate is less common. Unlike fingolimod or siponimod where ALC returns to baseline soon after discontinuation, prolonged lymphopenia after discontinuation may occur with dimethyl fumarate. 26 In addition, rare cases of progressive multifocal leukoencephalopathy (PML; a sometimes fatal opportunistic viral infection of the CNS) has been linked to dimethyl fumarate-induced lymphopenia, and a case of PML which occurred after an ALC of less than 500/lL that persisted for greater than 6 months prompted a FDA label change in 2014, which expands on lymphocyte monitoring recommendations. 26 While severe lymphopenia as a risk factor for PML remains controversial, it does highlight the importance of appropriate laboratory monitoring and follow up. 55 
Patient Case Part 5: Rebound Relationships
After 3 years on fingolimod the patient has had no relapses, no radiographic or clinical progression of disease, and ALCs have remained at or above 200/lL without any recent illnesses. Upon follow-up, the patient shares plans to relocate out of state for a new job opportunity in 2 months. This move will involve changing insurance providers and finding a new clinician. The patient is nervous about how to continue taking fingolimod until seen by a new clinician.
Fingolimod should not be abruptly discontinued without a plan to transition to an alternative DMT because of risk of rebound in persons with relapsing MS. Clinical rebound syndrome has been reported within 4 to 16 weeks of patients stopping fingolimod and is consistent with signs/ symptoms of a severe clinical relapse such as drastic increases in new and/or enhancing lesions on MRI and new or worsening MS symptoms. 23, 56 Similarly, risk of disease rebound after discontinuation is also high with natalizumab as a number of case studies have reported an increase in disease activity beyond that of prenatalizumab levels. 17, 57, 58 While the most effective management strategy to prevent rebound syndrome remains unclear, expert clinicians recommend transitioning to an alternative HE-DMT before the effects of fingolimod or natalizumab wear off. Based on experience, it is the authors' practice to transition patients to a HE-DMT within 4 to 8 weeks after the last natalizumab infusion and within 4 weeks after the last fingolimod dose.
Since the patient will soon be without a clinician and possibly without fingolimod for an unknown length of time, switching to alternative HE-DMT prior to losing current insurance coverage would be ideal. Based on clinical experience, an anti-CD20 agent may be the best option given it may help prevent clinical rebound syndrome after discontinuing fingolimod. Anti-CD20 agents are HE-DMTs with clinical effects lasting for at least 6 months after receiving a dose, which allows the patient time to establish care. While the anti-CD20 agent, ocrelizumab, is FDA-approved for MS, rituximab was the precursor to its development and has been used off-label for many years in European countries and later in the United States. 59 Either option would be appropriate, and choice would most likely be dictated by insurance coverage, copay, and provider preference.
Conclusion
The management of MS continues to rapidly evolve. Treatment options with greater efficacy and potential for altering the course are now available. Shared decision making and patient preferences remain key factors in DMT selection. However, treatment customization should also consider patient-specific negative prognostic factors both at diagnosis and throughout the course of treatment. Identification of these factors can further stratify therapy approach using the HE-DMTs, which then requires that benefits be balanced with sometimes very serious risks. Ongoing research will provide more direction as to which strategy is the safest and most effective for achieving a NEDA-like goal of treatment.
